资料显示，武汉农尚环境股份有限公司位于湖北省武汉市江岸区健康街66号绿地·汉口中心(二期)S11号 楼27层办公(7)室-办公(9)室，成立日期2000年4月28日，上市日期2016年9月20日，公司主营业务涉及园 林绿化工程设计、施工、养护及苗木培育业务。主营业务收入构成为：算力综合服务86.91%，园林绿 化工程11.07%，其他2.02%。 农尚环境所属申万行业为：建筑装饰-基础建设-园林工程。所属概念板块包括：湖北自贸区、集成电 路、新型城镇化、PPP概念、算力概念等。 11月27日，农尚环境（维权）盘中上涨2.10%，截至09:53，报8.27元/股，成交932.23万元，换手率 0.39%，总市值24.25亿元。 资金流向方面，主力资金净流入6.97万元，大单买入29.03万元，占比3.11%，卖出22.06万元，占比 2.37%。 农尚环境今年以来股价涨44.33%，近5个交易日跌2.01%，近20日跌2.71%，近60日跌22.05%。 分红方面，农尚环境A股上市后累计派现4380.86万元。近三年，累计派现0.00元。 责任编辑：小浪快报 截至11月10日，农尚环境股东户数1.20万，较上期 ...

航天电子今年以来股价涨19.75%，近5个交易日跌0.65%，近20日跌9.73%，近60日跌8.96%。 资料显示，航天时代电子技术股份有限公司位于北京市海淀区丰滢东路1号，成立日期1990年7月18日， 上市日期1995年11月15日，公司主营业务涉及主要从事测控通信、机电组件、集成电路、惯性导航以及 其他航天技术应用产品的研发、生产和销售。航天精密惯性仪表专业制造、液浮惯性器件制造、光纤陀 螺及光纤传感系统制造、电线电缆产品制造、位置姿态测量系统解决方案服务。主营业务收入构成为： 军品99.34%，民品0.39%，其他(补充)0.27%。 航天电子所属申万行业为：国防军工-航天装备Ⅱ-航天装备Ⅲ。所属概念板块包括：北斗导航、卫星互 联网、湖北自贸区、传感器、无人机等。 11月26日，航天电子盘中下跌2.02%，截至10:47，报10.67元/股，成交3.90亿元，换手率1.09%，总市值 352.04亿元。 截至9月30日，航天电子股东户数15.60万，较上期增加1.06%；人均流通股21145股，较上期减少 1.04%。2025年1月-9月，航天电子实现营业收入88.35亿元，同比减少4.32%；归母 ...

11月26日，人福医药（维权）盘中上涨2.08%，截至10:32，报19.65元/股，成交1.37亿元，换手率 0.46%，总市值320.73亿元。 资金流向方面，主力资金净流入500.79万元，特大单买入622.12万元，占比4.53%，卖出105.76万元，占 比0.77%；大单买入1942.03万元，占比14.15%，卖出1957.60万元，占比14.27%。 人福医药今年以来股价跌14.79%，近5个交易日跌1.01%，近20日跌7.18%，近60日跌6.78%。 资料显示，人福医药集团股份公司位于湖北省武汉东湖高新区高新大道666号，成立日期1993年3月30 日，上市日期1997年6月6日，公司主营业务涉及医药、医疗器械、生殖健康等产品及技术的研发、生 产、销售及技术服务。主营业务收入构成为：销售商品99.47%，提供劳务0.36%，其他(补充)0.17%。 人福医药所属申万行业为：医药生物-化学制药-化学制剂。所属概念板块包括：湖北自贸区、券商相 关、仿制药、体外诊断、创新药等。 截至9月30日，人福医药股东户数6.94万，较上期增加38.71%；人均流通股22222股，较上期减少 27.91% ...

11月24日，塞力医疗（维权）盘中上涨2.04%，截至10:46，报21.02元/股，成交8840.99万元，换手率 2.02%，总市值44.18亿元。 资金流向方面，主力资金净流入407.57万元，特大单买入109.93万元，占比1.24%，卖出129.12万元，占 比1.46%；大单买入1165.16万元，占比13.18%，卖出738.40万元，占比8.35%。 截至9月30日，塞力医疗股东户数7.93万，较上期增加73.49%；人均流通股2650股，较上期减少 36.58%。2025年1月-9月，塞力医疗实现营业收入8.57亿元，同比减少39.64%；归母净利润-8724.41万 元，同比减少55.72%。 分红方面，塞力医疗A股上市后累计派现2707.41万元。近三年，累计派现0.00元。 机构持仓方面，截止2025年9月30日，塞力医疗十大流通股东中，财通优势行业轮动混合A（011201） 位居第六大流通股东，持股122.82万股，相比上期增加58.48万股。广发医疗保健股票A（004851）位居 第七大流通股东，持股122.36万股，为新进股东。招商丰韵混合A（006364）位居第九大流通股东，持 ...

11月24日，烽火通信盘中上涨2.04%，截至10:22，报22.05元/股，成交1.80亿元，换手率0.69%，总市值 284.13亿元。 截至9月30日，烽火通信股东户数11.93万，较上期减少6.90%；人均流通股9928股，较上期增加9.08%。 2025年1月-9月，烽火通信实现营业收入170.72亿元，同比减少19.30%；归母净利润5.13亿元，同比增长 30.28%。 分红方面，烽火通信A股上市后累计派现37.91亿元。近三年，累计派现4.94亿元。 机构持仓方面，截止2025年9月30日，烽火通信十大流通股东中，香港中央结算有限公司位居第二大流 通股东，持股2133.05万股，相比上期增加557.16万股。南方中证500ETF（510500）位居第四大流通股 东，持股1110.20万股，相比上期增加53.96万股。易方达智造优势混合A（011300）位居第十大流通股 东，持股651.41万股，为新进股东。 责任编辑：小浪快报 资金流向方面，主力资金净流出430.92万元，特大单买入678.92万元，占比3.77%，卖出1504.77万元， 占比8.35%；大单买入3682.52万元，占比20 ...

嘉必优所属申万行业为：基础化工-化学制品-食品及饲料添加剂。所属概念板块包括：宠物经济、合成 生物、化妆品、多胎概念、湖北自贸区等。 截至9月30日，嘉必优股东户数8362.00，较上期增加1.01%；人均流通股20127股，较上期减少1.00%。 2025年1月-9月，嘉必优实现营业收入4.28亿元，同比增长10.56%；归母净利润1.29亿元，同比增长 54.18%。 分红方面，嘉必优A股上市后累计派现2.43亿元。近三年，累计派现1.03亿元。 11月21日，嘉必优盘中下跌2.04%，截至10:09，报23.04元/股，成交2331.54万元，换手率0.60%，总市 值38.78亿元。 资金流向方面，主力资金净流入25.49万元，特大单买入0.00元，占比0.00%，卖出100.50万元，占比 4.31%；大单买入571.01万元，占比24.49%，卖出445.02万元，占比19.09%。 嘉必优今年以来股价涨22.36%，近5个交易日跌7.36%，近20日跌4.20%，近60日跌17.63%。 今年以来嘉必优已经1次登上龙虎榜，最近一次登上龙虎榜为3月14日，当日龙虎榜净买入1850.19万 元；买入 ...

Core Viewpoint - Huagong Technology's stock has shown significant volatility and growth in 2023, with a year-to-date increase of 69.65% and a recent decline over the past 20 days of 11.67% [1][2] Financial Performance - For the period from January to September 2025, Huagong Technology achieved a revenue of 11.038 billion yuan, representing a year-on-year growth of 22.62%, and a net profit attributable to shareholders of 1.321 billion yuan, up 40.92% year-on-year [2] - The company has distributed a total of 1.087 billion yuan in dividends since its A-share listing, with 0.452 billion yuan distributed over the last three years [3] Stock Market Activity - As of November 18, Huagong Technology's stock price was 73.12 yuan per share, with a market capitalization of 73.522 billion yuan and a trading volume of 1.003 billion yuan [1] - The stock has appeared on the "龙虎榜" (a list of stocks with significant trading activity) six times this year, with the most recent appearance on September 30, where it recorded a net buy of -1.909 billion yuan [1] Shareholder Structure - As of September 30, 2025, Huagong Technology had 189,400 shareholders, an increase of 101.14% from the previous period, with an average of 5,306 circulating shares per shareholder, down 50.28% [2] - The second-largest circulating shareholder is Hong Kong Central Clearing Limited, holding 38.9396 million shares, a decrease of 7.8374 million shares from the previous period [3]

Core Viewpoint - Guangxun Technology's stock has shown a mixed performance in recent trading, with a year-to-date increase of 11.94% but a decline in the last five and twenty trading days [1][2] Financial Performance - For the period from January to September 2025, Guangxun Technology achieved a revenue of 8.532 billion yuan, representing a year-on-year growth of 58.65% [2] - The net profit attributable to shareholders for the same period was 719 million yuan, reflecting a year-on-year increase of 54.95% [2] Stock Market Activity - As of November 18, Guangxun Technology's stock price was 58.11 yuan per share, with a market capitalization of 46.886 billion yuan [1] - The stock has experienced a net inflow of 12.627 million yuan from main funds, with significant buying and selling activity noted [1] Shareholder Information - As of September 30, 2025, the number of shareholders increased to 147,300, up by 13.14% from the previous period [2] - The average number of circulating shares per shareholder decreased by 10.88% to 5,292 shares [2] Dividend Distribution - Guangxun Technology has distributed a total of 1.641 billion yuan in dividends since its A-share listing, with 537 million yuan distributed over the last three years [3] Institutional Holdings - As of September 30, 2025, Hong Kong Central Clearing Limited was the fourth-largest circulating shareholder, increasing its holdings by 4.0608 million shares [3] - New institutional shareholders include Debon Xinxing Value A and Guotai Junan CSI All Share Communication Equipment ETF [3]

Core Viewpoint - The stock of Dier Laser has experienced a decline in recent trading sessions, with a notable drop of 9.70% over the last five trading days, reflecting market volatility and potential investor concerns [1]. Financial Performance - For the period from January to September 2025, Dier Laser achieved a revenue of 1.781 billion yuan, representing a year-on-year growth of 23.69% [2]. - The net profit attributable to the parent company for the same period was 496 million yuan, showing a year-on-year increase of 29.39% [2]. Shareholder Information - As of September 30, 2025, the number of shareholders for Dier Laser was 19,700, a decrease of 12.16% from the previous period [2]. - The average number of circulating shares per shareholder increased by 13.85% to 8,491 shares [2]. Dividend Distribution - Dier Laser has cumulatively distributed 507 million yuan in dividends since its A-share listing, with 282 million yuan distributed over the past three years [3]. Institutional Holdings - As of September 30, 2025, the third-largest circulating shareholder is Invesco Great Wall New Energy Industry Fund A, holding 5.2669 million shares, an increase of 13,500 shares from the previous period [3]. - Hong Kong Central Clearing Limited is a new sixth-largest shareholder, holding 3.5118 million shares [3]. - Zhuque Hengxin One-Year Holding Fund reduced its holdings by 759,700 shares, now holding 3.1540 million shares, while E Fund's ChiNext ETF also saw a reduction of 482,600 shares, now holding 2.8893 million shares [3].

Core Viewpoint - Renfu Pharmaceutical's stock has experienced a decline of 11.71% year-to-date, with a recent drop of 2.02% on November 17, 2023, indicating potential challenges in the market [1]. Financial Performance - For the period from January to September 2025, Renfu Pharmaceutical reported a revenue of 17.883 billion yuan, a year-on-year decrease of 6.58%, while the net profit attributable to shareholders was 1.689 billion yuan, reflecting a year-on-year growth of 6.22% [2]. - Cumulative cash dividends since the company's A-share listing amount to 3.113 billion yuan, with 1.779 billion yuan distributed over the past three years [3]. Shareholder Information - As of September 30, 2025, the number of shareholders for Renfu Pharmaceutical increased to 69,400, a rise of 38.71%, while the average circulating shares per person decreased by 27.91% to 22,222 shares [2]. - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited holds 42.1832 million shares, a decrease of 1.3907 million shares compared to the previous period [3].